HK1257237A1 - 預防和治療脂肪肝的藥物及其用途 - Google Patents
預防和治療脂肪肝的藥物及其用途Info
- Publication number
- HK1257237A1 HK1257237A1 HK18116273.4A HK18116273A HK1257237A1 HK 1257237 A1 HK1257237 A1 HK 1257237A1 HK 18116273 A HK18116273 A HK 18116273A HK 1257237 A1 HK1257237 A1 HK 1257237A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- medicine
- preventing
- fatty liver
- treating fatty
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611161347 | 2016-12-15 | ||
CN201611162237 | 2016-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257237A1 true HK1257237A1 (zh) | 2019-10-18 |
Family
ID=62656680
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116273.4A HK1257237A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療脂肪肝的藥物及其用途 |
HK18116275.2A HK1257239A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療肥胖症的藥物及其用途 |
HK18116276.1A HK1257240A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途 |
HK18116270.7A HK1257234A1 (zh) | 2016-12-15 | 2018-12-19 | 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途 |
HK18116272.5A HK1257236A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療高脂血症的藥物及其用途 |
HK18116269.0A HK1257233A1 (zh) | 2016-12-15 | 2018-12-19 | 預防動脈粥樣硬化及其併發症的藥物及其用途 |
HK18116702.5A HK1257583A1 (zh) | 2016-12-15 | 2018-12-28 | 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途 |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116275.2A HK1257239A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療肥胖症的藥物及其用途 |
HK18116276.1A HK1257240A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途 |
HK18116270.7A HK1257234A1 (zh) | 2016-12-15 | 2018-12-19 | 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途 |
HK18116272.5A HK1257236A1 (zh) | 2016-12-15 | 2018-12-19 | 預防和治療高脂血症的藥物及其用途 |
HK18116269.0A HK1257233A1 (zh) | 2016-12-15 | 2018-12-19 | 預防動脈粥樣硬化及其併發症的藥物及其用途 |
HK18116702.5A HK1257583A1 (zh) | 2016-12-15 | 2018-12-28 | 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (8) | CN108210914A (zh) |
HK (7) | HK1257237A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108671226A (zh) * | 2018-08-08 | 2018-10-19 | 广州铭康生物工程有限公司 | 有效治疗中心静脉导管并发症的药物及其用途 |
CN110093412A (zh) * | 2019-03-29 | 2019-08-06 | 南方医科大学南方医院 | 用于诊断动脉粥样硬化的分子标志物ugp2及应用 |
CN111100928A (zh) * | 2020-01-09 | 2020-05-05 | 武汉科技大学 | 动脉粥样硬化生物标志物及动脉粥样硬化诊断试剂盒 |
US20230139956A1 (en) * | 2020-02-26 | 2023-05-04 | Talengen International Limited | Method and drug for preventing and treating abnormal blood pressure condition |
CN112305120B (zh) * | 2020-10-30 | 2022-02-08 | 河北医科大学第二医院 | 代谢物在动脉粥样硬化性脑梗死中的应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408431A (zh) * | 2001-09-21 | 2003-04-09 | 北京华兴生生物技术有限公司 | 治疗与新生血管生成相关疾病的基因工程药物 |
JP2005525798A (ja) * | 2002-02-06 | 2005-09-02 | トロムスドルフ ゲーエムベーハー ウント コー.カーゲー アルツナイミッテル | 微生物内での組み換えタンパク質の生産方法 |
AU2003301809A1 (en) * | 2002-05-13 | 2004-06-07 | Children's Hospital Los Angeles | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
CN100469370C (zh) * | 2002-12-06 | 2009-03-18 | 法布罗根股份有限公司 | 一种稳定HIFα的制剂在制备调节脂肪代谢的药物中的应用 |
WO2004052856A1 (en) * | 2002-12-10 | 2004-06-24 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
EP1666469A4 (en) * | 2003-09-11 | 2008-12-03 | Inst Med Molecular Design Inc | INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR |
AU2005238464B2 (en) * | 2004-04-22 | 2011-01-27 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
WO2006095713A1 (ja) * | 2005-03-08 | 2006-09-14 | Institute Of Medicinal Molecular Design. Inc. | プラスミノゲンアクチベータインヒビター-1阻害剤 |
JPWO2007111242A1 (ja) * | 2006-03-24 | 2009-08-13 | ロート製薬株式会社 | メタボリック症候群改善剤 |
DK2056864T3 (en) * | 2006-08-28 | 2014-03-10 | Omnio Healer Ab | CANDIDATES AGAINST INFECTION |
AU2007309226B2 (en) * | 2006-10-20 | 2012-09-20 | Dow Global Technologies Llc | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
US20090239868A1 (en) * | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
JP5470046B2 (ja) * | 2007-10-23 | 2014-04-16 | 株式会社医薬分子設計研究所 | Pai−1産生抑制剤 |
CA2767612A1 (en) * | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
CN107412724A (zh) * | 2009-08-12 | 2017-12-01 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
EP2566890A4 (en) * | 2010-05-03 | 2013-11-20 | Abbvie Inc | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE |
ES2583082T3 (es) * | 2011-01-05 | 2016-09-19 | Thrombogenics N.V. | Variantes de plasminógeno y plasmina |
EP2680837A4 (en) * | 2011-03-03 | 2015-06-03 | Tersus Pharmaceuticals Llc | COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE |
CN102188699A (zh) * | 2011-05-06 | 2011-09-21 | 南京农业大学 | 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用 |
RU2604810C2 (ru) * | 2011-08-12 | 2016-12-10 | Тромбодженикс Н.В. | Варианты плазминогена и плазмина |
CN102532326B (zh) * | 2011-11-18 | 2017-06-09 | 南京大学 | 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用 |
KR20160035077A (ko) * | 2013-08-13 | 2016-03-30 | 사노피 | 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도 |
WO2015026494A2 (en) * | 2013-08-20 | 2015-02-26 | Trustees Of Dartmouth College | Methods for treating tissue fibrosis |
-
2017
- 2017-06-19 CN CN201710466263.5A patent/CN108210914A/zh active Pending
- 2017-06-19 CN CN201710466253.1A patent/CN108210906A/zh active Pending
- 2017-06-19 CN CN201710465496.3A patent/CN108210895A/zh active Pending
- 2017-06-19 CN CN201710465724.7A patent/CN108210900A/zh active Pending
- 2017-06-19 CN CN201710465497.8A patent/CN108210896A/zh active Pending
- 2017-06-19 CN CN201710466235.3A patent/CN108210904A/zh active Pending
- 2017-06-19 CN CN201710465721.3A patent/CN108210898A/zh active Pending
- 2017-06-19 CN CN201710465726.6A patent/CN108210902A/zh active Pending
-
2018
- 2018-12-19 HK HK18116273.4A patent/HK1257237A1/zh unknown
- 2018-12-19 HK HK18116275.2A patent/HK1257239A1/zh unknown
- 2018-12-19 HK HK18116276.1A patent/HK1257240A1/zh unknown
- 2018-12-19 HK HK18116270.7A patent/HK1257234A1/zh unknown
- 2018-12-19 HK HK18116272.5A patent/HK1257236A1/zh unknown
- 2018-12-19 HK HK18116269.0A patent/HK1257233A1/zh unknown
- 2018-12-28 HK HK18116702.5A patent/HK1257583A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1257236A1 (zh) | 2019-10-18 |
CN108210895A (zh) | 2018-06-29 |
HK1257234A1 (zh) | 2019-10-18 |
HK1257233A1 (zh) | 2019-10-18 |
CN108210898A (zh) | 2018-06-29 |
CN108210906A (zh) | 2018-06-29 |
HK1257239A1 (zh) | 2019-10-18 |
CN108210896A (zh) | 2018-06-29 |
CN108210902A (zh) | 2018-06-29 |
CN108210904A (zh) | 2018-06-29 |
HK1257583A1 (zh) | 2019-10-25 |
CN108210914A (zh) | 2018-06-29 |
HK1257240A1 (zh) | 2019-10-18 |
CN108210900A (zh) | 2018-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262416A (en) | Materials and methods for the treatment of hemoglobin diseases | |
HK1252873A1 (zh) | 用於癌症治療和預防的疫苗 | |
SG10202101986UA (en) | Tetracycline compounds and methods of treatment | |
SG11201706767RA (en) | Materials and methods for treatment of hemoglobinopathies | |
HK1257237A1 (zh) | 預防和治療脂肪肝的藥物及其用途 | |
ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
HK1250950A1 (zh) | 曲美他嗪在製備防治肝病的藥物中的用途 | |
IL265955A (en) | Therapeutic compounds and methods of use thereof | |
HK1259545A1 (zh) | 用於治療癌症的bcl-2抑制劑和mek抑制劑組合產品 | |
IL246779A0 (en) | Methods for the treatment and prevention of kidney disorders and fatty liver disorders | |
IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
GB2558021B (en) | Composition for treatment and/or nutrition of poultry | |
IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
HK1257587A1 (zh) | 預防和治療肝纖維化的藥物及其用途 | |
ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
ZA201900984B (en) | Methods and compositions for the treatment of warts | |
HK1258056A1 (zh) | 治療性化合物和其使用方法 | |
GB201511799D0 (en) | Composition and methods of treatment | |
GB201621737D0 (en) | Compositions and methods of treatment | |
HK1249035A1 (zh) | 降低成像後胰腺炎風險的組合物和方法 | |
GB201605127D0 (en) | Composition and methods of treatment | |
EP3225237A4 (en) | Fatty acid amides for the prevention and/or treatment of steatohepatitis | |
GB201522936D0 (en) | A combination of Chinese medicine treating fatty liver | |
GB201418640D0 (en) | Agents and methods for treatment of cancer | |
AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases |